Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Drug Causing Severe Side Effects Is Withdrawn

By HospiMedica staff writers
Posted on 15 Dec 2000
A prescription medication approved to treat irritable bowel syndrome (IBS) in women has been voluntarily withdrawn from the market by the manufacturer at the request of the U.S. More...
Food and Drug Administration (FDA). The drug, alosetron hydrochloride (Lotronex), is the product of Glaxo Wellcome (London, UK).

The company's action followed an analysis by the U.S. Food and Drug Administration (FDA) of reports of serious side effects since the drug's approval in February, including the deaths of five patients. Other side effects that were reported included 49 cases of ischemic colitis and 21 cases of severe constipation. In all, 34 cases resulted in hospitalization.

Following its analysis, the FDA met with Glaxo Wellcome to consider a number of marketing options, including restricting distribution of the drug or market withdrawal. At the conclusion of the meeting, Glaxo informed the FDA that it would voluntarily withdraw the drug. In the meantime, the FDA is advising patients taking the drug to contact their healthcare providers in order to discuss alternative treatments.



Related Links:
FDA
Glaxo Wellcome

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.